Neurologic Diseases and Neurogenetics

Summary

This group undertakes the challenges of developing advanced treatments for patients with movement disorders, refractory epilepsy, neuropathies, myasthenia, myopathies, etc., in addition to the work carried out with the Multiple Sclerosis Unit and the Multidisciplinary Unit for Patients with Amyotrophic Lateral Sclerosis (thanks to the collaboration with the Miquel Valls Foundation).he group works in the development of new diagnostic and prognostic biomarkers and clínical, epidemiological studies in neurologial diseases.

619 Publications

Strategic lines

Biomarkers in neurological disease: ALS, MS, Alzheimer's Disease...
New therapeutic strategies in Neurological Diseases
Epidemiology of Neurological Disease: ALS, neurovascular disorders, dementia, Multiple Sclerosis
Lexical access disorders in speech production
Prothrombotic mechanisms in patients with Stroke
Neurophysiological markers in postanoxic patients
Neuronal networks and Epilepsy
Personalized and Precision Medicine in neurological disease
Prognostic studies in movement disorders, multiple sclerosis, ALS, neurovascular, dementia...

Selected Publications

- Munoz Vendrell A, Sala Padro J, Jaraba S, Reynes Llompart G, Veciana M, Mora J, Falip M. Functional neuroimaging in nonepileptiform electroencephalographic patterns in status epilepticus. Acta Neurol. Scand. 2021;144(6):687-694. doi:10.1111/ane.13515. IF:3,21.

- Gifreu A, Falip M, Sala Padro J, Mongay N, Morandeira F, Camins A, Naval Baudin P, Veciana M, Fernandez M, Pedro J, Garcia B, Arroyo P, Simo M. Risk of Developing Epilepsy after Autoimmune Encephalitis. Brain Sci. 2021;11(9):doi:10.3390/brainsci11091182. IF:3,39.

- Andres Benito P, Gelpi E, Jove M, Mota Martorell N, Obis E, Portero Otin M, Povedano M, Pujol A, Pamplona R, Ferrer I. Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. Neuropathol. Appl. Neurobiol. 2021;47(4):544-563. doi:10.1111/nan.12681. IF:8,09.

- Alemany M, Nunez A, Falip M, Lara B, Paipa A, Quesada H, Mora P, de Miquel MA, Barranco R, Pedro J, Cardona P. Acute symptomatic seizures and epilepsy after mechanical thrombectomy. A prospective long-term follow-up study. SEIZURE-EUR J EPILEP. 2021;895-9. doi:10.1016/j.seizure.2021.04.011. IF:3,18.

- Andrés Benito P, Domínguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging-US. 2021;13(20):23871-23871. doi:10.18632/aging.203667. IF:5,68.

Selected Projects

- 18PSJ028. Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis. (HR17-00777). FUNDACIÓ "LA CAIXA"; FUNDACIO IDIBELL; FUNDACION MANUEL PEREZ (FMP); UNIV. AUTONOMA BARCELONA. 2018-2022. IP:POVEDANO PANADES,MONICA.

- 18MAR003. ADDRESSING CHALLENGES OF STROKE CARE IN THE XXIst CENTURY: REACHING REPERFUSION THERAPY TOP RATES, ELIMINATING INEQUALITIES IN ACCESS AND DEALING WITH BIG DATA. (201712-32). BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION (BSC-CNS); FUNDACIÓ ICTUS; FUNDACIO IDIBELL; FUNDACIÓ LA MARATÓ DE TV3. 2018-2021. IP:MARTINEZ YELAMOS,ANTONIO.

- 18MAR002. The Chemical Optimization of Cerebral Embolectomy (CHOICE) Trial. (201707-31). FUND. CLINIC PER RECERCA BIOMEDICA; FUNDACIO IDIBELL; FUNDACIÓ IMIM; FUNDACIÓ INSTITUT DE RECERCA VALL Dâ€™HEBRON; FUNDACIÓ LA MARATÓ DE TV3. 2018-2021. IP:MARTINEZ YELAMOS,SERGIO.

- ACL:2022-010-1. A PHASE 3, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RELDESEMTIV IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). (CY5031). CYTOKINETICS, INC. 2021IP:MONICA POVEDANO PANADES.

- ACL:2021-080-1. ESTUDIO DE FASE III DE NO INFERIORIDAD, ALEATORIZADO, ABIERTO, DE GRUPOS PARALELOS Y MULTICÉNTRICO PARA INVESTIGAR LA FARMACOCINÉTICA, LA FARMACODINÁMICA, LA SEGURIDAD Y LOS EFECTOS RADIOLÓGICOS Y CLÍNICOS DE OCRELIZUMAB SUBCUTÁNEO EN COMPARACIÓN CON OCRELIZUMAB INTRAVENOSO EN PACIENTES CON ESCLEROSIS MÚLTIPLE. (CN42097). ROCHE FARMA S.A. 2021IP:SERGIO MARTINEZ YELAMOS.

More information

PROJECTS

Title: Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis
PI: Povedano Padanes, Mònica
Coordinator: Universitat Autònoma de Barcelona- UAB (Project Leader: Dr. Rubèn López Vales)
Call reference: Health Research 2017 Call for proposals, expediente: HR17-00777
Funder: Fundació “la Caixa”